Technical Analysis for CRDF - Cardiff Oncology, Inc.

Grade Last Price % Change Price Change
D 10.04 10.33% 0.94
CRDF closed up 10.33 percent on Wednesday, May 5, 2021, on 3.13 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up
Historical CRDF trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
180 Bullish Setup Bullish Swing Setup 0.00%
Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Earnings Movers Other 0.00%
Multiple of Ten Bullish Other 0.00%
20 DMA Support Bullish 10.33%
Overbought Stochastic Strength 10.33%
Fell Below 50 DMA Bearish 4.80%
Older End-of-Day Signals for CRDF ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Upper Bollinger Band Resistance about 11 hours ago
Rose Above Upper Bollinger Band about 12 hours ago
Up 10% about 12 hours ago
60 Minute Opening Range Breakout about 14 hours ago
Up 1 ATR about 14 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Cardiff Oncology, Inc. Description

Cardiff Oncology, Inc., a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic Colorectal Cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer; Phase I clinical trial with various chemotherapies and targeted therapeutics, such as Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) used in leukemias, lymphomas, and solid tumor cancers. It primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.


Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Cancer Clinical Medicine Pharmaceutical Solid Tumors Drugs Oncology Lymphoma Cancer Treatments Prostate Cancer Phosphate Chemotherapy Acute Myeloid Leukemia Antineoplastic Drugs Leukemia Targeted Therapy Colorectal Cancer Takeda Pharmaceutical Company Advanced Solid Tumors Resistant Prostate Cancer Solid Tumor Cancers Adenosine Leukemias Metastatic Colorectal Cancer Metastatic Castration Resistant Prostate Cancer Chemotherapies Nektar Therapeutics

Is CRDF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 25.5
52 Week Low 0.825
Average Volume 882,093
200-Day Moving Average 12.24
50-Day Moving Average 9.70
20-Day Moving Average 9.04
10-Day Moving Average 9.41
Average True Range 0.69
ADX 15.71
+DI 24.68
-DI 14.92
Chandelier Exit (Long, 3 ATRs ) 8.16
Chandelier Exit (Short, 3 ATRs ) 10.03
Upper Bollinger Band 10.18
Lower Bollinger Band 7.91
Percent B (%b) 0.94
BandWidth 25.14
MACD Line -0.05
MACD Signal Line -0.23
MACD Histogram 0.1819
Fundamentals Value
Market Cap 354.66 Million
Num Shares 35.3 Million
EPS -2.73
Price-to-Earnings (P/E) Ratio -3.68
Price-to-Sales 848.95
Price-to-Book 21.61
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.60
Resistance 3 (R3) 11.46 10.81 11.34
Resistance 2 (R2) 10.81 10.41 10.88 11.25
Resistance 1 (R1) 10.42 10.16 10.62 10.56 11.17
Pivot Point 9.77 9.77 9.86 9.84 9.77
Support 1 (S1) 9.38 9.37 9.58 9.52 8.91
Support 2 (S2) 8.73 9.12 8.80 8.83
Support 3 (S3) 8.34 8.73 8.74
Support 4 (S4) 8.48